TAIPEI, Taiwan, Dec. 19, 2024 (GLOBE NEWSWIRE) — Leading Pump Brand – Walrus Pump (TPEX: 6982) officially debuted on the Taiwan OTC market on the 18th at an underwriting price of NTD 51. Amid a global trend of steady growth in demand for pumps, the company not only maintains its position as the market leader in Taiwan, but it is also actively expanding its international footprint, at the same time focusing on innovative technology development and sustainable development strategies. Through expanding into the Southeast Asian market, introducing smart application technology water pumps, and enhancing ESG-compliant products, Walrus Pump’s operational performance continues to rise. From January to November this year, its cumulative revenue reached NTD 1.47billion, reflecting a 15.22% annual growth, demonstrating impressive results.

In recent years, Walrus Pump has actively strengthened its international market expansion, particularly on marketing and promotion strategies for the Southeast Asia market. In recent years, key export markets for the company include Thailand, Vietnam, and Cambodia. Its subsidiary, SUZHOU WALRUS PUMP, has launched the (TP8 series) in ASEAN markets, leveraging local tariff advantages to enhance competitiveness. Building on its successful experience in the Thai distribution market, the company plans to replicate this in other Southeast Asian markets, as well as promoting the WALRUS brand through local online social media platforms to further expand its brand influence.

Simultaneously, to meet the market’s demand for high-performance products, Walrus Pump is actively investing in the development of IoT-enabled smart pumps and brushless DC motors (BLDC). The BLDC speed-control pump developed by the company not only improves energy efficiency but also reduces power consumption. These products are particularly suitable for servo cooling systems and electric vehicle (EV) charging station cooling systems, offering energy-saving features that significantly enhance product competitiveness.

In 2024, Walrus Pump’s industrial series products have successfully been applied in server cooling systems, while its newly developed cooling circulation pump, specifically designed for EV charging stations, provides liquid cooling during charging.

As global ESG policies continue to tighten, Walrus Pump has been proactively advancing its ESG strategies and consistently investing resources in green product development. The company’s products incorporate high-efficiency energy saving motors and controller technologies, meeting RoHS and CE certifications, with green design concepts integrated from the design stage. Walrus Pump’s operational momentum remains optimistic moving forward.

Walrus Pump Spokesman +886 2 2768-0189

AMAZING CREATIVITY INTEGRATED MARKETING CO., LTD Mr. Hu 886 952-343-528

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/724e1184-786d-40c6-ae48-16297d49bb21

The post Innovation and International Expansion: Walrus Pump Welcomes Global Demand for Water Pumps appeared first on Crypto Insider.

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –

– In clinical testing SYMVESS was observed to have high rates of patency, or blood flow,
and low rates of amputation and infection –

– Highly experienced sales team already recruited and trained in preparation for commercial launch –

DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

“We are very excited and proud to provide patients suffering from arterial injury with a novel treatment option. SYMVESS has been made possible by our innovative bioengineering science along with the contributions of many patients, healthcare providers and Humacyte team members.” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “SYMVESS approval in this first indication for arterial injury repair is a milestone for regenerative medicine overall, as well as for Humacyte. The FDA’s full approval of SYMVESS is a transformational event for the Company and our bioengineering technology platform. Even more importantly, we believe SYMVESS provides a new means of treating patients with devastating arterial injuries, which is a population that has not benefited from substantial innovation in decades. We look forward with great excitement to our upcoming commercial launch of SYMVESS, and we have recruited and trained a terrific team to execute on our sales and marketing missions.”

“The approval of a vascular conduit that resists infection and remodels into native arteries is an extraordinary technological advancement that will have a huge impact on the quality of trauma care around the world,” said Charles J. Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the V005 clinical trial. “SYMVESS is perfectly sized to treat most injuries, has excellent handling properties, and reduces time necessary to save both life and limbs. The Humacyte team has responsibly and scientifically solved a major clinical problem that I believe will reduce the amputation rate for traumatic vascular injury. They should be congratulated on an accomplishment that will undoubtedly advance our specialty to the next level.”

“I believe that SYMVESS will revolutionize vascular trauma care and be profoundly beneficial to our patients,” said Rishi Kundi, MD, Surgical Critical Care, Vascular Surgery, University of Maryland Medical System. “From my experience so far, SYMVESS will allow reconstructions that are currently impracticable because of contamination and infection. It will make reconstructions that we now perform with prosthetic or even biologic grafts more successful. I am most excited about the promise that SYMVESS holds for the long-term experience of our patients. I hope that, with SYMVESS, the 19-year-old patient with vascular reconstruction after trauma will no longer spend the six decades after their surgery anticipating disaster, but that their chances for reintervention will be no different than if they had autologous conduit.”

SYMVESS, or the ATEV, is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. While harvesting vein from a trauma patient takes valuable surgical time, SYMVESS is available off-the-shelf, and does not require further injuring the patient to obtain vascular repair material. Humacyte’s BLA included positive results from the V005 pivotal Phase 2/3 clinical study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. SYMVESS was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds, and industrial accidents. It was utilized by vascular and trauma surgeons in Level 1 Trauma centers throughout the U.S. and Israel to repair severe limb-threatening and life-threatening injuries, and in front-line hospitals in Ukraine to treat wartime injuries. Results from these studies were published in JAMA Surgery on November 20, 2024. In the civilian and military clinical studies, SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.

“Finally, we have an innovative technology for battlefield vascular injuries using a tissue engineered human arterial replacement that can resist infections that are so prevalent in modern combat zones,” added Dr. Fox. “SYMVESS shows promise to reduce amputation rates since an alternative conduit for war injuries is often needed but up until now has not been a good option.”

“The FDA approval of SYMVESS will make it the preferred conduit for complex vascular injuries, and particularly those at risk for infection.” said Ernest E. Moore, MD, FACS, Director of Research at the Ernest E. Moore Shock Trauma Center at Denver Health, a clinical investigator in the V005 trial. “I look forward to using SYMVESS in my practice.”

Arterial injuries resulting from vascular trauma are common in civilian and military populations, frequently resulting in the loss of life or limb. In civilian populations, trauma injuries are primarily caused by motor vehicle, workplace and sporting accidents, gun violence, mass casualty terrorist attacks, stabbings, blunt trauma, and iatrogenic injuries (injuries caused by medical treatment or examination). Autologous vein, which is harvested from the patient’s body through a separate surgical incision, is the current preferred conduit for arterial repair. However, harvesting of autologous vein is not always feasible due to damage to veins or to the limbs. Harvesting autologous vein is also an invasive procedure that requires additional time and resources, delaying the time from injury to restoration of blood flow for the injured patient. In contrast, SYMVESS may be removed from its packaging and ready for implantation within minutes and does not involve creating additional incisions in already-injured patients.

The SYMVESS trauma program was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in May 2023, a Biologic License Application (BLA) was submitted to the FDA in December 2023, and in February 2024 the FDA granted a Priority Review. On August 9, 2024, the FDA informed Humacyte that it needed additional time to complete its review of the BLA, although there were no outstanding pre-approval requirements for SYMVESS as of that date. The FDA completed its review today, granting full approval.

INDICATION

SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. 

WARNINGS AND PRECAUTIONS

• Graft Rupture

Vascular graft rupture has occurred in patients treated with SYMVESS. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

• Anastomotic Failure

Anastomotic failure has occurred in patients treated with SYMVESS. In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

• Thrombosis

Thrombosis has occurred in patients treated with SYMVESS. In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS.

• Transmission of Infectious Diseases

SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum). The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and
pain.

Please see full Prescribing Information, including Boxed Warning, for SYMVESS.

Humacyte filed the BLA with trauma clinical data based upon the accepted statistical analysis plan. These data were also peer reviewed and published in JAMA Surgery on November 20, 2024. In the package insert, the FDA elected to exclude the synthetic graft comparator that was in the statistical analysis plan. The FDA also applied a different imputing methodology for SYMVESS patients who did not have a day 30 assessment. Nine patients without day 30 data were imputed as failures of patency in the package insert, despite the fact that they had favorable patency results at the last assessment. In addition, multiple patients who never underwent an amputation were imputed as failures of limb salvage.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of acellular tissue engineered vessels (ATEVs), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication was approved by the FDA in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize our ATEV in the United States under the brand name SYMVESS in vascular trauma repair; the statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials; the anticipated characteristics and performance of our ATEVs; our ability to successfully complete, preclinical and clinical trials for our ATEVs; the anticipated benefits of the ATEV relative to existing alternatives; the anticipated commercialization of our ATEVs and our ability to manufacture at commercial scale; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our quarterly report on Form 10-Q for the quarter ended September 30, 2024, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

The post Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma appeared first on Crypto Insider.

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased Rentokil Initial PLC (NYSE: RTO) American Depository Shares (“ADSs”) between December 1, 2023 and September 10, 2024. Rentokil provides pest control, hygiene, and wellness services worldwide.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Rentokil Initial PLC (RTO) Misled Investors Regarding its Integration of Terminix

According to the complaint, during the class period, defendants failed to disclose that: (1) Rentokil experienced levels of disruption in the early pilots of its Terminix integration; (2) Rentokil experienced significant, ongoing, self-inflicted execution challenges integrating Terminix; (3) the disruption and execution challenges imperiled Rentokil’s integration plan for Terminix; (4) Rentokil and Terminix were still two separate businesses that were not yet integrated; and (5) Rentokil’s failure to integrate Terminix negatively impacted the Company’s business and operations, particularly organic revenue growth in North America.

Plaintiff alleges that news of the failed integration came to light on September 11, 2024, when Rentokil provided an unscheduled “Trading Update,” announcing that the Company now expected only 1% organic revenue growth in North America for the second half of 2024—well below the Company’s prior guidance. The Company further revealed this was “a manifestation of execution challenges.”

On this news, the price of Rentokil ADSs fell $6.65 per ADS, or more than 21%, from a closing price of $31.60 per ADS on September 10, 2024, to a closing price of $24.95 per ADS on September 11, 2024.

What Now: You may be eligible to participate in the class action against Rentokil Initial PLC. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 27, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Rentokil Initial PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a9c821-b578-47c9-8880-6d0600f1038e

The post RTO Class Action Alert: Rentokil Initial PLC Stockholders with Significant Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit appeared first on Crypto Insider.

BEIJING, Dec. 18, 2024 (GLOBE NEWSWIRE) — The “2024 Beijing Forum on Swift Response to Public Complaints” opened at the China National Convention Center in Beijing on December 18. The permanent theme of the forum is “People’s City, Better Future”, and the 2024 annual theme is “Modernizing for People-centered Urban Governance”.

 A Media Snippet accompanying this announcement is available by clicking on this link. 

The forum features an opening ceremony and main forum, six parallel sessions, documentary watching, “Approaching 12345” and other supporting activities, as well as a closing ceremony. 

A series of outcomes of the forum were released at the opening ceremony: Compilation of Research Papers on Swift Response to Public Complaints in Beijing (2024); Cases of Urban Governance Innovation (2024); Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024).

The forum is co-sponsored by the Chinese Academy of Social Sciences, China Media Group (CMG), the CPC Beijing Municipal Committee and the People’s Government of Beijing Municipality. The international academic journal “Journal of Comparative Policy Analysis: Research and Practice” (JCPA) was invited as a co-organizer of the forum.

Source: The Organizing Committee of The 2024 Beijing Forum on “Swift Response to Public Complaints”

The post 2024 Beijing Forum on Swift Response to Public Complaints opens appeared first on Crypto Insider.

NEW ORLEANS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company’s securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.

What You May Do

If you purchased securities of Cassava and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-sava/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 10, 2025.

About the Lawsuit

Cassava and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 25, 2024, the Company disclosed topline results for the first of its two ongoing Phase 3 studies on its leading drug candidate, simufilam, the “ReThink-ALZ” study, that indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.

On this news, the price of Cassava’s shares fell approximately 83%, from a closing price of $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024.

The case is Crocker v. Cassava Sciences, Inc., et al., No. 24-cv-1525.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Chicago, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

The post CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA appeared first on Crypto Insider.

NEW ORLEANS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Marqeta, Inc. (NasdaqGS: MQ), if they purchased the Company’s securities between August 7, 2024 and November 4, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Marqeta and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit http://ksfcounsel.com/cases/nasdaqgs-mq/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 7, 2025.

About the Lawsuit

Marqeta and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (1) the Company understated the regulatory challenges affecting its business outlook; (2) the Company would have to cut its guidance for the fourth quarter of 2024; and (3) as a result, defendants’ statements were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The case is Wai v. Marqeta, Inc., et al., No. 24-cv-08874.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Chicago, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

The post MARQETA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Marqeta, Inc. - MQ appeared first on Crypto Insider.

Los Angeles, Dec. 16, 2024 (GLOBE NEWSWIRE) — Los Angeles, California –

Advanced Networks has announced its latest strategic move to strengthen its presence in California, with a focus on Managed IT Services Los Angeles. This step, highlighted on the Advanced Networks website, is aimed at supporting local businesses by offering innovative technology solutions tailored to their specific needs.

The company has carved out a niche by addressing complex tech issues with practical solutions. As the demand for IT Support Los Angeles grows, Advanced Networks is ready to provide businesses with the essential tools to navigate the ever-changing tech landscape. From network security and cloud solutions, detailed on their services page on their website, to comprehensive IT support, they are set to offer services that are both effective and efficient.

A representative of Advanced Networks stated, “Our mission in expanding our Managed IT Services Los Angeles is to support local businesses in optimizing their operations with reliable and scalable IT solutions. We believe our services will enable businesses to focus on their core operations without the concern of IT disruptions.”

The expansion not only includes providing services but also a full suite of IT Consulting Los Angeles. This initiative offers strategic planning, as outlined in their consulting section on their website, and technical support to ensure solutions align with the unique goals of each business. Advanced Networks is committed to fostering innovation and making sure businesses have all the necessary resources.

The company representative further noted, “We are excited to provide our extensive expertise to businesses in Los Angeles. Our approach focuses on understanding the individual needs of each client, allowing us to craft customized solutions that are both effective and practical.”

As a dependable partner in technology transformation, Advanced Networks is set on delivering industry-leading solutions. Their services aim to boost efficiency in business environments and simplify operations. By integrating their robust technological frameworks, businesses can operate with greater confidence and experience less downtime.

The company is dedicated to constantly enhancing its offerings to meet the shifting demands of the IT landscape. This ongoing improvement assures that businesses using their services, which are further described at their website, are not only keeping up with technology but thriving through personalized strategies and solid infrastructures.

In the coming months, Advanced Networks plans to connect with local business communities by participating in events and workshops. This community engagement is a key part of their growth strategy, with Managed IT Services Los Angeles at the forefront.

Advanced Networks is committed to maintaining transparency and excellence in all client interactions, building a foundation of trust that’s been central to their success. Their approach to IT Support Los Angeles emphasizes proactive management, aiming to prevent issues before they arise and providing peace of mind to businesses invested in tech advancement.

As part of a larger initiative, Advanced Networks seeks to deepen relationships with industry stakeholders to enhance their service offerings. By doing so, they expect to expand the range of solutions available to Los Angeles businesses, addressing diverse needs with precision and skill. Their commitment to quality and reliability ensures clients have consistent and effective IT infrastructure management at their disposal.

Advanced Networks understands that keeping up with a rapidly evolving tech world is essential. This drives their commitment to continuous development and adaptation, ensuring they align with the latest advancements to equip clients with optimal resources for success. For more on their ongoing technological advancements, visit their website.

Through their expertise in IT Consulting Los Angeles, Advanced Networks envisions a future where technology smoothly integrates into business functions, making operations run more efficiently. Their proactive consultations help businesses assess their current tech status and get advice tailored to maximize improvement opportunities.

Overall, this new chapter for Advanced Networks in Los Angeles highlights their dedication to helping businesses achieve new levels of success with effective IT solutions. Their focus on Managed IT Services Los Angeles and expansion into IT consulting underscores their commitment to delivering reliable, forward-thinking solutions. The blend of strategic insight and technical support makes Advanced Networks a trusted partner for businesses seeking growth and innovation.

###

For more information about Advanced Networks, contact the company here:

Advanced Networks
Advanced Networks
(213) 873-7620
contact@adv-networks.com
L.A. Office
10960 Wilshire Blvd. #1415
Los Angeles, CA 90024

O.C. Office
1340 Reynolds Ave. #116
Irvine, CA 92614

The post Advanced Networks Amplifies IT Support and Cybersecurity in Los Angeles with Targeted Managed Services Expansion appeared first on Crypto Insider.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce that, pursuant to its news release of November 25, 2024, it has completed the first tranche of its non-brokered private placement for aggregate gross proceeds of C$2,148,250, pursuant to which it sold the following (together, the “Offering”):

• 2,271,000 non-flow through common shares in the capital of the Company (each, a “Share”) at a price of C$0.25 per Share for gross proceeds of C$567,750 from the sale of the Shares; and
• 5,450,000 critical flow-through common shares of the Company (each, a “FT Share”, and collectively with the Shares, the “Offered Securities”) at a price of C$0.29 per FT Share for gross proceeds of C$1,580,500 from the sale of FT Shares.

Red Cloud Securities Inc. acted as a finder in connection with the Offering and received $110,635 and 381,500 share purchase warrants (each, a “Finder’s Warrant”). Each Finder’s Warrant is exercisable into one Share (each, a “Finder’s Warrant Share”) at a price of $0.33 per Finder’s Warrant Share until December 16, 2026.

Nicholas Luksha, the Chief Executive Officer of Mustang, stated “We are very excited to be closing the first tranche of the financing. This capital raise provides us with resources to engage the various contractors required to complete our phase one work plan as we endeavor to prove up numerous prospective drill targets.”

Each FT Share is issued as a “flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”). The Company intends to use the proceeds of the Offering for the exploration of the Company’s uranium projects in the Athabasca Basin in Saskatchewan as well as for general working capital purposes. The gross proceeds from the issuance of the FT Shares will be used to incur resource exploration expenses which will constitute “Canadian exploration expenses” as defined in subsection 66.1(6) of the Tax Act and “flow through critical mineral mining expenditures” as defined in subsection 127(9) of the Tax Act, which will be renounced with an effective date no later than December 31, 2024 to the purchasers of the FT Shares in an aggregate amount not less than the gross proceeds raised from the issue of the FT Shares. The maximum offering size of the FT Shares was increased by $580,499.96 after investors expressed greater interest in the FT Shares than was previously anticipated by the Company, while the total amount of Offered Securities remains within the maximum offering size disclosed by the Company in its news release dated November 25, 2024.

The securities issued under the Offering are subject to a hold period expiring on April 17, 2025.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Mustang Energy Corp.

Mustang is a resource exploration company focused on acquiring and developing high-potential uranium and critical mineral assets. The Company is actively exploring its properties in the Athabasca Basin of Saskatchewan, Canada. Mustang’s flagship property, Ford Lake, covers 7,743 hectares in the prolific eastern Athabasca Basin, while its Cigar Lake East and Roughrider South projects span 2,901 hectares in the Wollaston Domain. Mustang has also established its footprint in the Cluff Lake region of the Athabasca Basin with the acquisition of the Yellowstone Project and further expanded its presence in the south central region of the Athabasca Basin with the Dutton Project.

On behalf of the board of directors,

“Nicholas Luksha”

Nicholas Luksha
CEO and Director

For further information, please contact:

Mustang Energy Corp.
Attention: Nicholas Luksha, CEO and Director
Phone: (604) 838-0184

Forward-Looking Statements Disclaimer

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends”, “believes” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to the intended use of proceeds of the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the CSE nor the Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

The post Mustang Energy Corp. Announces Closing of First Tranche of Strategic Financing for Gross Proceeds of C$2,148,250 appeared first on Crypto Insider.

NEW YORK, Dec. 15, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN), (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced the pricing of an underwritten public offering of 2,000,000 ordinary shares (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) at a public offering price of $1.25 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of $2,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the ordinary shares (and/or Pre-funded Warrants) are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares (and/or Pre-funded Warrants) at the public offering price less discounts and commissions, to cover over-allotments. The offering is expected to close on December 17, 2024, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering primarily for costs directly related to sales and marketing, for research and development, working capital and general corporate purposes, including personnel costs, capital expenditures and the costs of operating as a public company. The Company may also use a portion of the net proceeds to repay indebtedness outstanding.

ThinkEquity is acting as sole book-running manager for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-282966), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 1, 2024 and declared effective on November 12, 2024. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Roadzen Inc.

Roadzen Inc. (Nasdaq: RDZN) is a global technology company transforming auto insurance using advanced artificial intelligence (AI). Thousands of clients, from the world’s leading insurers, carmakers, and fleets to dealerships and auto insurance agents, use Roadzen’s technology to build new products, sell insurance, process claims, and improve road safety. Roadzen’s pioneering work in telematics, generative AI, and computer vision has earned recognition as a top AI innovator by publications such as Forbes, Fortune, and Financial Express. Roadzen’s mission is to continue advancing AI research at the intersection of mobility and insurance, ushering in a world where accidents are prevented, premiums are fair, and claims are processed within minutes, not weeks. Headquartered in Burlingame, California, the Company has 360 employees across its global offices in the U.S., India, U.K. and France. To learn more, please visit www.roadzen.ai.

Cautionary Statement Regarding Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” and “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, statements regarding the expected completion of the offering described in this press release and the intended use of proceeds of such offering, if completed. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in “Risk Factors” in our SEC filings, including the annual report on Form 10-K we filed with the SEC on July 1, 2024, any subsequently filed quarterly reports and other documents we subsequently file with the SEC. We urge you to consider these factors, risks and uncertainties carefully in evaluating the forward-looking statements contained in this press release. All subsequent written or oral forward-looking statements attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included in this press release are made only as of the date of this release. Except as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For more information, please contact:

Investor Contacts: IR@roadzen.ai

Media Contacts:
Roadzen: Sanya Soni sanya@roadzen.ai or media@roadzen.ai
Gutenberg: roadzen@thegutenberg.com

The post Roadzen Inc. Announces Pricing of Public Offering appeared first on Crypto Insider.

Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global healthcare analytical testing services market size will reach a value of USD 15.55 Billion by 2031, with a CAGR of 11.2% during the forecast period (2024-2031). The market’s main driving factors are the number of companies in the pharmaceutical and medical device industries that outsource analytical testing services, increased clinical trials in need of analytical testing, and the rising emphasis on biosimilars. The industry has grown as a result of the COVID-19 pandemic. Additionally, since the pandemic, the market has seen a quick development in medications and treatments for its prevention, which has increased the demand for analytical testing services. 

Browse in-depth TOC on the “Healthcare Analytical Testing Services Market” 

Pages – 168

Tables – 61

Figures – 70

To Learn More About This Report, Request a Free Sample Copy – https://www.skyquestt.com/sample-request/healthcare-analytical-testing-services-market

Healthcare Analytical Testing Services Market Overview: 

Pharmaceutical Analytical Testing Services to Hold Significant Growth due to Increasing Regulatory Requirements 

The dominance of pharmaceutical analytical testing services in the global healthcare analytical testing services market is driven by increasing regulatory requirements, the rising complexity of drug formulations, and the demand for quality assurance. Those services provide strict compliance, improved drug safety, and support an increasing demand for accurate reliable testing in the pharmaceutical industry, reflecting a promising global healthcare analytical testing services market outlook. 

Make an Inquiry to Address your Specific Business Needs: https://www.skyquestt.com/speak-with-analyst/healthcare-analytical-testing-services-market

Pharmaceutical & Biopharmaceutical Companies to Lead Market due to Increasing Demand for Drug Development 

Pharmaceutical and biopharmaceutical companies dominate the global healthcare analytical testing services market due to the increasing demand for drug development and manufacturing. This calls for a specific analytical service meant for ensuring safety, efficacy, and compliance with all world standards along the lines of the production process. It is really meant for stringent regulatory compliance, product quality assurance, and testing the biologics during their production, which supports positive global healthcare analytical testing services market trends. 

Asia Pacific to Dominate Market due to Advanced Technological Capabilities & Stringent Regulatory Frameworks 

North America’s dominance in the global healthcare analytical testing services market is fueled by robust healthcare infrastructure, advanced technological capabilities, and stringent regulatory frameworks. These aspects are the ones driving up a high demand for the proper testing services through which pharmaceutical innovations are done, clinical tests take place, and compliance with regulatory standards is met, securing the place of North America as the leader in the global healthcare analytical testing services market outlook. 

Healthcare Analytical Testing Services Market Insight 

Drivers: 

1. Reliable Analytical Testing Services to Ensure Compliance 
2. Growing Complexity of Drug Formulations 
3. Growth in Biologics and Biosimilars 

Restraints: 

1. High Cost of Analytical Testing Services 
2. Achieving Fast Turnaround Times 
3. Increasing Concerns Around Data Security in Testing Services 

Take Action Now: Secure Your Healthcare Analytical Testing Services Market Today – https://www.skyquestt.com/buy-now/healthcare-analytical-testing-services-market

Prominent Players in Healthcare Analytical Testing Services Market 

• Eurofins Scientific (Luxembourg)
• Laboratory Corporation of America Holdings (US)
• SGS S.A. (Switzerland)
• Charles River Laboratories (US)
• WuXi AppTec Co. Ltd. (China)
• Element Materials Technology (UK)
• Thermo Fisher Scientific, Inc. (US)
• Pace Analytical Services LLC (US)
• Intertek Group plc (UK)
• IQVIA Inc. (US)
• Merck KGaA (Germany)
• Source BioScience (UK)
• Almac Group (UK)
• ICON Plc (Ireland)
• Frontage Laboratories, Inc. (US)
• STERIS Plc (US)
• Sartorius AG (Germany)
• ALS Life Science (US)
• Syneos Health, INC (US)
• Medpace Holdings, Inc. (US) 

Key Questions Answered in Global Healthcare Analytical Testing Services Market Report 

• What will be the projected market size of the global healthcare analytical testing services industry by 2031? 
• What are the primary factors driving the growth of healthcare analytical testing services? 
• Which region is expected to dominate the market, and what factors contribute to its dominance? 

Read Healthcare Analytical Testing Services Market Report Today – https://www.skyquestt.com/report/healthcare-analytical-testing-services-market

This report provides the following insights: 

Analysis of key drivers (Pandemic increased demand for testing services, higher incidences of chronic conditions, emphasis on drug safety & efficacy), restraints (Regulatory delays in approvals, healthcare budget constraints) opportunities (Growth of telemedicine, rise of point-of-care diagnostics) influencing the growth of healthcare analytical testing services market. 

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the healthcare analytical testing services market. 
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the healthcare analytical testing services market. 
• Market Development: Comprehensive information on lucrative emerging regions 
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the market 
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players. 

Related Reports:

Biodefense Market is growing at a CAGR of 5.03% in the forecast period (2024-2031)

Gene Editing Market is growing at a CAGR of 6.80% in the forecast period (2024-2031)

Varicose Veins Treatment Market is growing at a CAGR of 6.32% in the forecast period (2024-2031)

Digital Genome Market is growing at a CAGR of 18.5% in the forecast period (2024-2031)

Membrane Chromatography Market is growing at a CAGR of 14.90% in the forecast period (2024-2031)

About Us: 

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.  

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia-Pacific. 

Contact Us: 

Mr. Jagraj Singh 
SkyQuest Technology 
1 Apache Way, 
Westford, 
Massachusetts 01886 
USA (+1) 351-333-4748 
Email: sales@skyquestt.com 
Visit Our Website: https://www.skyquestt.com/ 

The post Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology appeared first on Crypto Insider.